ViVita seeks to advance the fields of tissue engineering and regenerative medicine by expanding knowledge of xenogeneic approaches for generating clinically acceptable replacement tissues and organs.
ViVita is establishing the safety profile and manufacturing pipeline of BARE patches following completion of R&D. The text also refers to ECM niche-dependent regenerative capacity and the resulting in vivo function of BARE.
Maelene L. Wong is co-founder and chief executive officer and leads efforts to translate ViVita's platform technology from the lab bench and commercialize the resulting products.
The American Heart Association (AHA) reports that 100,000 heart valve replacements are performed annually in the U.S., representing a $1.7 billion burden.
The page describes the extracellular matrix (ECM) as foundational to tissue and organ function and discusses harnessing animal-derived ECM that avoids immune rejection in humans.
ViVita's patented SPEAR Process removes immunological barriers from animal-derived tissues and produces the BARE Patch, an immune-compatible biomaterial.
ViVita's patented SPEAR Process removes immunological barriers from animal-derived tissues and produces the BARE Patch, an immune-compatible biomaterial.
